arrow
T

Thomas B. Karasic

University of Pennsylvania
H指数:22
被引数:2,648

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial

吉西他滨和nab-紫杉醇联合或不联合VDR激动剂帕立骨化醇治疗转移性胰腺癌: 一项随机,多臂,磨合期试验

2026-05-250
PRE
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

精准肿瘤学中耐药性解码模型:胆管癌对FGFR抑制剂的获得性耐药

2024-12-011
OAAI
Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications

I期首个人体研究初步结果,该研究评估了共价PI3Kα抑制剂TOS-358在表达PI3Kα突变或扩增的实体瘤患者中的疗效。

2024-09-010
PRE
PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation

PYNNACLE II期临床试验:评估rezatapopt(PC14586)在携带TP53 Y220C突变的实体瘤中的疗效

2024-09-010
PRE
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
2024-07-092
OAAI
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer

FOENIX-CCA2研究的简明语言摘要: futibatinib用于晚期胆管癌患者

2024-06-170
OAAI
Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers
2023-12-123
OAAI
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Divarasib联合西妥昔单抗治疗KRAS G12C-positive结直肠癌: 1b期临床试验

2023-12-0531
OAAI
Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
2023-04-147
PRE
Liquid biopsy signature combining copy number instability and mutant KRAS detection is associated with survival for patients with metastatic pancreatic cancer
2023-04-040
PRE
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Futibatinib治疗FGFR2-Rearranged肝内胆管癌

2023-01-19243
OA
A PHASE 1 STUDY EXPLORING THE SAFETY AND TOLERABILITY OF THE SMALL MOLECULE PD-L1 INHIBITOR, INCB086550, IN PATIENTS WITH SELECT ADVANCED TUMORS
2022-11-070
OA